Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Department of Justice
Argus Health
Harvard Business School

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,549,892

« Back to Dashboard

Summary for Patent: 5,549,892

Title: Enhanced in vivo uptake of glucocerebrosidase
Abstract:A pharmaceutical composition comprising remodelled recombinant glucocerebrosidase (GCR) is described that provides a therapeutic effect at doses that are lower then those required using remodelled naturally occurring GCR. A method of treating patients with Gaucher's disease using remodelled recombinant GCR is also provided. In vivo uptake of exogenous molecules can be determined by extracting a mixture of cells from a subject, enriching the target cells in vitro, lysing the cells and determining the amount of exogenous molecules.
Inventor(s): Friedman; BethAnn (Arlington, MA), Hayes; Michael (Acton, MA)
Assignee: Genzyme Corporation (Cambridge, MA)
Application Number:08/080,855
Patent Claim Types:
see list of patent claims
Composition; Use;

No matches for this query

International Patent Family for Patent: 5,549,892

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0401362► Subscribe
Spain2093642► Subscribe
Canada2006709► Subscribe
Canada2339888► Subscribe
Germany68926569► Subscribe
Austria138686► Subscribe
JapanH03502289► Subscribe
Japan2893481► Subscribe
JapanH03503721► Subscribe
World Intellectual Property Organization (WIPO)9007573► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Cantor Fitzgerald
Daiichi Sankyo
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus